(Q43054038)

13 November 2017

title

Novel targeted therapies in inflammatory breast cancer (English)

1 reference

13 November 2017

author name string

Massimo Cristofanilli

series ordinal

1

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

116

1 reference

13 November 2017

issue

11 Suppl

1 reference

13 November 2017

page(s)

2837-2839

1 reference

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

High incidence of HER-2 positivity in inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25172

7 January 2021

Identifiers

DOI

10.1002/CNCR.25172

1 reference

13 November 2017

1 reference